Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Capricor Therapeutics (CAPR) EBT Margin (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of EBT Margin data on record, last reported at 364548.09% in Q3 2025.

  • For Q3 2025, EBT Margin fell 36399288.0% year-over-year to 364548.09%; the TTM value through Sep 2025 reached 7295.32%, up 741601.0%, while the annual FY2024 figure was 403.62%, 31485.0% down from the prior year.
  • EBT Margin reached 364548.09% in Q3 2025 per CAPR's latest filing, down from 194260.36% in the prior quarter.
  • Across five years, EBT Margin topped out at 615.05% in Q4 2024 and bottomed at 364548.09% in Q3 2025.
  • Average EBT Margin over 5 years is 38654.4%, with a median of 398.19% recorded in 2022.
  • Peak YoY movement for EBT Margin: skyrocketed 450477bps in 2021, then tumbled -36399288bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 2482.54% in 2021, then skyrocketed by 68bps to 800.77% in 2022, then surged by 99bps to 6.86% in 2023, then skyrocketed by 9067bps to 615.05% in 2024, then tumbled by -59372bps to 364548.09% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 364548.09% in Q3 2025, 194260.36% in Q1 2025, and 615.05% in Q4 2024.